Skip Navigation



Journal of the National Cancer Institute Advance Access published online on October 26, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp373
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lee, S. M.
Right arrow Articles by Hackshaw, A.
PubMed
Right arrow Articles by Lee, S. M.
Right arrow Articles by Hackshaw, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Anti-Angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Siow Ming Lee

AlLan Hackshaw

Affiliations of authors: Department of Oncology, University College Hospital, London, UK (SML); Cancer Research UK & University College London Cancer Trials Centre, London, UK (SML, AH)

Correspondence to: Siow Ming Lee, MD, PhD, FRCP, Department of Oncology, University College Hospital, 250 Euston Rd, London NW1 2PG, UK (e-mail: sm.lee@uclh.nhs.uk).

The first 10% of the full text of this article appears below.

We welcome the contribution of Musallam and Taher on the issues of increased thromboembolic events (TEE) and possible further hypothetical biological and clinical explanations for the decreased survival associated with thalidomide treatment in small . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?